Navigation Links
The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
Date:6/2/2008

CINCINNATI, June 2 /PRNewswire/ -- The International Rett Syndrome Foundation announced today that Antony Horton Ph.D. will join the Foundation as Chief Scientific Officer, beginning July 1. Dr. Horton will oversee the foundation's research portfolio and its network of Rett Clinics, a series of clinics throughout the US with established neuromedical research and treatment centers. In addition, Dr. Horton will assist the IRSF Board of Directors in growing its funding pool and broadening its network of research partners. IRSF is the world's leading private funder of basic and clinical Rett syndrome research. IRSF was formed in 2007 by the merger of The International Rett Syndrome Association and the Rett Syndrome Research Foundation.

"Dr. Horton joins us during an exciting time for Rett syndrome research since recent breakthroughs give new insight into the function of the MECP2 gene that causes Rett syndrome and last year's discovery of the reversibility of Rett symptoms in mice models," said Kathryn Kissam, IRSF Board Chair. "We have the opportunity to fund crucial new research with the potential to impact lives and advance the understanding of Rett syndrome and related disorders. Dr. Horton's knowledge of the science of drug discovery and his experience in research program management will help the Foundation to shape and advance our mission of improving the lives of children living with Rett while searching for a cure to this devastating disease."

According to Dr. Horton, "As Chief Scientific Officer, I am eager to bring my scientific vision and research management experience to bear on the IRSF mission. I look forward to developing a portfolio of research programs that will accelerate translation of research discoveries into therapies to treat and cure Rett syndrome."

Dr. Horton earned his Ph.D. in developmental neurobiology at St. Andrew's University in Scotland. Currently, Dr. Horton is the Director of Scientific Affairs for the Alzheimer's Drug Discovery Foundation in New York. Previously, he served for several years as Program Director at the Juvenile Diabetes Research Foundation and as a post doctoral scientist at Rockefeller University Laboratory of Molecular Biology.

About Rett Syndrome

While there are over 3,800 known cases of Rett Syndrome in the United States which predominantly strikes only girls, the disorder is genetically linked to more widespread neurological disorders such as autism and schizophrenia. Rett symptoms begin to manifest between the first six to eighteen months of life and in most cases will eventually incapacitate the afflicted children so that they cannot survive without constant care. The disorder causes seizures, respiratory and gastrointestinal abnormalities, and a variety of muscular and motor impairments.

IRSF is the world's most comprehensive non-profit organization dedicated to providing thorough and accurate information about Rett syndrome, offering informational and educational family support, and stimulating research aimed at accelerating treatments and a cure for Rett syndrome. To learn more about IRSF and Rett syndrome, visit http://www.rettsyndrome.org or call IRSF at 1-800-818-RETT.


'/>"/>
SOURCE The International Rett Syndrome Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology: